Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

A technology for analogs, derived peptides, applied in the field of Hsp60-derived peptides and peptide analogs for the inhibition and treatment of non-autoimmune diabetes, and can solve unmet problems

Inactive Publication Date: 2014-12-24
YEDA RES & DEV CO LTD
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] There is an unmet need for effective and safe compositions providing ingredients for the prevention, delay, suppression and treatment of non-autoimmune diabetes mellitus, namely T2D

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
  • Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
  • Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] Embodiment 1: T2D experimental animal model

[0147] Mice genetically predisposed to T2D (dp / dp or ob / ob strains, tolerant to leptin), and / or healthy C57BL / 6 mice induced to develop T2D by a high-fat diet, were used for in vivo evaluation of hsp60 peptides and similar The substance provides protection against T2D or the activity of treating T2D. The db / db model is described, eg, in Dray et al., Am. J. Physiol. Endocrinol Metab 2010, 298, E1161-E1169. In the high-fat diet model, diets (such as Harlan TM TD.0811 from Research Diets Inc. or D12492 from Research Diets Inc., containing 21% and 34.9% fat, respectively) started after weaning, and mice exhibited T2D before 10 weeks of age. These, and other animal models for T2D, are reviewed by Srinivasan and Ramarao (Indian J Med Res 2007, 125, 451-472).

[0148] In a typical experiment, groups of T2D mice (10 per group) were treated early in the disease (approximately 7-10 weeks of age). The negative control group consist...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60), and for suppression, prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277(TM), a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression, prevention or treatment of T2D.

Description

field of invention [0001] The present invention relates to a method for preventing, suppressing and treating non-autoimmune diabetes, comprising: administering a peptide derived from heat shock protein 60 (hsp60), or an analog thereof. The present invention is exemplified by the use of an hsp60 peptide analog represented as DiaPep277DiaPep277 for the treatment of type 2 diabetes (T2D). The present invention also relates to therapeutic regimens and formulations suitable for the administration of DiaPep277 and other Hsp60 peptides and analogs for the inhibition or treatment of T2D. Background of the invention [0002] Type 2 diabetes (T2D, also known as non-insulin-dependent diabetes, NIDDM or adult-onset diabetes) is the most common form of diabetes, accounting for 90% of diabetes cases. It is a metabolic disorder characterized by hyperglycemia in the setting of relative peripheral insulin resistance and insulin deficiency. Diabetes affects 7 percent of people ages 45 to 64...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K45/06A61P3/10
CPCA61K38/1709A61K45/06C07K14/47A61P1/18A61P25/00A61P3/00A61P35/00A61P3/06A61P43/00A61P9/00A61P3/10A61K2300/00A61K38/17
Inventor 艾润·R·科恩拉阿南·马加利特
Owner YEDA RES & DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com